Bruker

Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) Life Science, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI Life Science segment includes enabling life science tools based on magnetic resonance technology. The BSI Nano segment offers x-ray instruments that use electromagnetic radiation with wavelengths to determine the characteristics of matter and the three-dimensional (3D) structure of molecules. The BEST segment consists of conducting materials, primarily metallic low temperature superconductors, for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research, and other applications. The company was founded by Gunther Laukien in 1960 and is headquartered in Billerica, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Bruker reports robust 2022 performance, eyes growth amid challenges

Bruker's strong financial performance in 2022, driven by organic revenue growth and strategic investments, positions the company for continued success.
While facing supply chain challenges and geopolitical risks, Bruker remains optimistic about growth opportunities in proteomics and spatial biology.
Confidence in 2023 outlook is supported by strong bookings, backlog visibility, and expectations of solid organic growth in key markets.

Bruker reports strong Q1 earnings, eyes spatial biology markets

Bruker's Q1 2023 performance showcased robust revenue growth and margin improvement, with strong demand across key segments and regions.
While facing challenges like margin declines and supply chain constraints, the company is well-positioned to capitalize on opportunities in spatial biology and proteomics markets.
By focusing on innovation, capacity investments, and addressing backlog delays, Bruker aims to sustain growth momentum and meet future demand expectations.
Overall, Bruker's strategic initiatives and market positioning indicate a positive outlook for continued growth and market leadership in the analytical instruments industry.

Bruker reports strong Q2 earnings, eyes global growth opportunities

Bruker's Q2 2023 performance reflects strong revenue and EPS growth, driven by demand across key segments and regions. The company's focus on innovation and global expansion positions it well for future growth.
While facing challenges such as high lead times and supply chain issues, Bruker is proactively managing costs and investing in capacity to meet demand. Opportunities for organic growth and profitability through strategic investments and pricing trends are on the horizon.
Overall, Bruker's Q2 2023 earnings call highlights a resilient performance, strategic strengths in R&D and global presence, challenges in capacity and logistics, and opportunities for sustained growth and profitability.

Bruker reports strong Q3 earnings and eyes sustainable growth

Bruker's Q3 2023 performance reflects robust revenue and earnings growth, supported by strong organic growth and strategic acquisitions.
While facing challenges in biopharma investments and China trends, Bruker's strengths lie in its elevated backlog and growth opportunities in green tech and academic funding.
The company's focus on high-end Life Science tools in China and long-term growth prospects position it well for sustained success.
Overall, Bruker's performance in Q3 2023 showcases resilience and strategic positioning for future growth.

Bruker excels in Q4 2023, eyes accelerated growth and acquisitions

Bruker's strong Q4 2023 performance showcased robust revenue and EPS growth, though challenges like margin pressure and geopolitical risks persist. With a focus on strategic acquisitions and market opportunities, Bruker aims for continued growth and innovation.

Bruker boosts revenue guidance after Q1 growth, faces margin challenges

Bruker's Q1 2024 performance showed growth despite margin challenges, with increased revenue guidance for the year.
Strong geographic revenue growth in the Americas and Europe contrasted with a decline in Asia Pacific.
Strategic acquisitions and focus on organic growth present opportunities for Bruker in 2024.
Challenges include margin compression, dilution from integration, and lower organic growth due to order distortions.

Bruker reports robust Q2 earnings, eyes growth in key sectors

Bruker's strong Q2 performance and strategic acquisitions are driving growth in key areas like spatial biology and molecular diagnostics.
While facing margin challenges due to recent acquisitions, the company remains confident in achieving operational excellence and margin expansion.
Maintaining mid-single-digit organic revenue growth and focusing on operational efficiency position Bruker for continued success in the market.
The company's outlook remains positive with opportunities for growth through acquisitions and market demand for its innovative solutions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bruker Corp. engages in the business of developing, manufacturing, and distributing high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) BioSpin, BSI Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID), BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI BioSpin segment includes life science tools based on magnetic resonance technology. The BSI CALID segment focuses on life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments, and solutions based on infrared and Raman molecular spectroscopy technologies and radiological and nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The BSI Nano segment offers advanced x-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments, analytical tools for electron microscopes and x-ray metrology, defect-detection equipment for semiconductor process control, handheld, portable, and mobile x-ray fluorescence spectrometry instruments, spark optical emission spectroscopy systems, and chip cytometry products and services for targeted spatial proteomics, multi-omics services, and products and services for spatial genomics research. The BEST segment is involved in superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare, and big science research. The company was founded by Emil Bruker and Günther Laukien in 1960 and is headquartered in Billerica, MA.

Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Bruker (BRKR) to Report a Decline in Earnings: What to Look Out for

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report third quarter 2024 financial results before market opening on Tuesday, November 5, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q3 2024 Earnings Webcast” hyperlink in the “Events & Presentations” section. A slide prese.

Bruker Announces Date and Time of Third Quarter 2024 Earnings Release and Webcast

DRESDEN, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--At the 23rd Human Proteome Organization World Congress, Bruker Corporation (Nasdaq: BRKR) announces advances in deep, unbiased and high-sensitivity 4D-Proteomics for robust, high- fidelity, large-scale studies - avoiding inherent cross-talk of affinity high-plex technologies. A. Enhanced specificity and proteome coverage using diagonal-PASEF Leveraging scanning quadrupole and trapped ion mobility spectrometry (TIMS), diagonal-PASEF was introduced in 2023 by ke.

Bruker Announces One-Hundred Dollar, Deep, High-Accuracy Plasma Proteome; Advances Glycoproteomics and Metaproteomics

Bruker announces the formation of the new Bruker Spatial Biology division.

BRKR Stock to Gain From Newly Formed Bruker Spatial Biology Division

BILLERCA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that the European Unified Patent Court (UPC) has ruled in favor of its NanoString business, invalidating European Patent No. 2794928B1 (the “928 Patent”), which has been asserted by 10x Genomics against NanoString's CosMx® Spatial Molecular Imager (SMI) products in Europe. Today's ruling follows the May 2024 decision of the German Federal Patent Court, which declared the 928 Patent invalid and revoked the patent.

European Unified Patent Court Rules in Favor of Bruker and NanoString, Invalidating Patent Asserted By 10x Genomics against NanoString's CosMx SMI Products

Biognosys announced its participation in the 23rd Human Proteome Organization (HUPO) World Congress from October 20 to October 24 in Dresden, Germany.

Biognosys Presents Major Innovations Across the Spectrum of Proteomics Research Applications at the HUPO World Congress

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced the formation of a new division, Bruker Spatial Biology, offering the most diverse and comprehensive solutions for spatial biology. Bruker Spatial Biology brings together in operational coordination three entities: the two businesses of NanoString Technologies and Canopy Biosciences, along with its subsidiary Bruker Spatial Genomics, Inc. (formerly known as Acuity Spatial Genomics, Inc.). Bruker Spatial Biology.

Bruker Announces Formation of New Bruker Spatial Biology Division

At the Neuroscience 2024 conference, Bruker released its latest OptoVolt module, which seamlessly integrates with Ultima 2Pplus microscope and NeuraLight 3D SLM.

BRKR Stock Might Gain From the Newly Launched OptoVolt Module

BRKR acquires Dynamic Biosensors or DBS. DBS's unique products, along with BRKR's SPR portfolio, should help the latter establish a leading biosensors business.

Bruker Stock Gains From Its Latest Acquisition of Dynamic Biosensors

CHICAGO--(BUSINESS WIRE)---- $BRKR #BRKR--At the Neuroscience 2024 conference, Bruker Corporation (Nasdaq: BRKR) today announced the release of the OptoVolt™ module to further expand the advanced neuroscience research capabilities on Bruker's Ultima multiphoton microscope platform. OptoVolt accelerates imaging speeds to beyond 1000 frames per second for the capture of millisecond dynamics of cell-to-cell neural communication. With the emergence of fluorescent voltage indicators, researchers are excited to meas.

Bruker Introduces Innovative Neuroscience Research Solution with High-Speed OptoVolt Voltage Imaging

Bruker's robust growth potential across its Nano segment is encouraging. Yet, unfavorable currency movement is likely to pose a challenge.

Here's Why You Should Retain BRKR Stock in Your Portfolio Now

MUNICH--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Dynamic Biosensors GmbH, a pioneering company known for its breakthroughs in biosensor development, which is based in Munich, Germany. This acquisition strengthens Bruker's biophysical portfolio for the analysis of molecular interactions and kinetics, offering deeper insights into both inter-molecular and molecule-single cell interactions in drug discovery or basic research. Dynamic Biosensors (DBS) de.

Bruker Acquires Dynamic Biosensors, a Pioneer of Single-Cell Interaction Cytometry Systems for Drug Discovery

Investors need to pay close attention to Bruker (BRKR) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Bruker (BRKR) Stock?

Dublin, Sept. 20, 2024 (GLOBE NEWSWIRE) -- The "Dermatology Diagnostic Devices Market (2024 Edition): Analysis by Type (Imaging Devices, Microscopes, Immunoassays, Molecular Diagnostics, Others), Application, End-user and Region: Insights and Forecast (2020-2030)" report has been added to ResearchAndMarkets.com's offering. This report provides a complete analysis of the Global Dermatology Diagnostic Devices industry for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030. The Global Dermatology Diagnostic Devices market showcased growth at a CAGR of 10.29% during 2020-2023. The market was valued at USD 7.57 billion in 2023, and is expected to reach USD 17.65 billion in 2030.

Assessment of the Dermatology Diagnostic Devices Market, 2020-2030, Featuring Strategic Analysis of Canfield Scientific, Leica Microsystems, Welch Allyn, Bruker, Heine Optotechnik & More

Biognosys' Spectronaut®, the leading vendor-agnostic software for DIA proteomics, is now directly available from Thermo Fisher Scientific under a reselling agreement End users can get access to Thermo Scientific mass spectrometry systems and Biognosys' Spectronaut software via a single offer issued by Thermo Fisher Thermo Fisher will directly quote and sell Biognosys' Spectronaut software from its product catalog ZURICH and NEWTON, Mass., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Biognosys, a leading inventor and provider of software solutions for mass spectrometry-based proteomics data analysis, today announced the rollout of a Value-added Reselling agreement for Biognosys' Spectronaut® software with Thermo Fisher Scientific.

Biognosys Enters Reselling Agreement for Spectronaut Proteomics Software with Leading Provider of Mass Spectrometry Systems

Bruker (BRKR) reported earnings 30 days ago. What's next for the stock?

Bruker (BRKR) Up 6.8% Since Last Earnings Report: Can It Continue?

BRKR's robust growth potential across its major segments is encouraging. Yet, macro woes and competitive pressure can pose challenges.

Should You Consider Retaining Bruker Stock in Your Portfolio Now?

Under a strategic partnership with Alamar Biosciences, Biognosys is a provider of choice of NULISA multiplex assay services for biopharma research The NULISAseq™ CNS Disease and Inflammation panels are now available for customers as a contract research service from Biognosys' high-end proteomics facility in Europe By offering the combination of NULISA affinity-based assays and TrueDiscovery® mass spectrometry-based plasma profiling with P2 Plasma Enrichment, Biognosys offers the industry's most comprehensive solutions for plasma proteomics ZURICH and NEWTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in next-generation proteomics solutions for drug discovery and development, announced today the commercial availability of NULISA proteomics assays for biomarker discovery in plasma and other biofluids.

Biognosys Announces Commercial Availability of NULISA™ Proteomics Assay Services for Biomarker Research

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences: 2024 Wells Fargo Healthcare Conference in Boston, MA Wednesday, September 4, 2024, at 10:15 a.m. Eastern Time Morgan Stanley 22nd Annual Global Healthcare Conference in New York City Friday, September 6, 2024, at 10:00 a.m. Eastern Time Live audiovisual webcasts of the presentation.

Bruker Corporation to Present at Upcoming Investor Conferences

Bruker (BRKR) installs the 1.2 GHz Avance NMR Spectrometer at KBSI, enabling advanced scientific discoveries.

Bruker (BRKR) Rolls Out the First 1.2 GHz NMR System in Asia

SEOUL, South Korea--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation is pleased to announce the successful installation and acceptance of a 1.2 GHz Avance® Nuclear Magnetic Resonance (NMR) spectrometer at the Korea Basic Science Institute (KBSI), just in time before the start of the ICMRBS 2024 conference in Korea. As the first 1.2 GHz NMR system in the Asia-Pacific region, it sets a new benchmark for molecular, cell biology and disease research by ultra-high field NMR. This underscores KBSI's unwavering co.

Bruker Announces Successful Installation of 1.2 GHz Avance® NMR Spectrometer at the Korea Basic Science Institute (KBSI)

Evaluate Bruker's (BRKR) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Bruker (BRKR) Reliance on International Sales: What Investors Need to Know

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on September 16, 2024 to stockholders of record as of September 2, 2024. About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develo.

Bruker Announces Quarterly Dividend

Bruker Corporation (NASDAQ:BRKR ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Joe Kostka - Associate Director, Investor Relations Frank Laukien - President and CEO Gerald Herman - Executive Vice President and CFO Conference Call Participants Puneet Souda - Leerink Partners Patrick Donnelly - Citi Rachel Vatnsdal - JPMorgan Tycho Peterson - Jefferies Doug Schenkel - Wolfe Research Josh Waldman - Cleveland Research Operator Good day. And welcome to the Bruker Corporation Second Quarter 2024 Earnings Call.

Bruker Corporation (BRKR) Q2 2024 Earnings Call Transcript

Bruker (BRKR) invests in NovAliX to accelerate advancements in drug discovery, combining cutting-edge biophysical methods and technologies to develop new treatments and enhance biopharma solutions.

News for Bruker Stock (BRKR)